Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (March 2024)
20 slides from Evofem Biosciences's investor presentation, Mar 28, 2024
Slide 1: Evofem Biosciences Investor Presentation March 2024
E¥OFEM BIOSCIENCES INVESTOR PRESENTATION MAR‘ 24
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘This presentation contains frvard looking statements within the meaning of The Privat Secures Ugo Reform At of 985 another Federal securities awn Some cases, jaca nt format looking tatemens by tems sch as ‘may wl’ “soul “expect” “lanai antpate “stategy “diet “ese” “sues “
Slide 3: 43.3M Potential Phexxi Users in the U.S.
ohe i. 43.3M POTENTIAL PHEXXI USERS IN THE U.S.? {lacie aci, citric acid, and potassium bitatate) Vaginal Gel 1.8%, 1%, 0.4% Us. MARKET BY ‘CONTRACEPTIVE METHOD! tutons} i 10.3M women use non-prescription contraceptives sos Nor-Remethods: barr methods; withdrawal ped abstinence; tracing: other, 4 os
Slide 4: Evofem Is Leading the Revolution
EVOFEM IS LEADING THE REVOLUTION Innovative women’s reproductive and sexual health solutions ‘THE FIRST AND ONLY ON-DEMAND, NON- HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL Vaginal pH Modulator Hormone-free FDA-approved for prevention of pregnancy Woman-controlled Used only when you need it Box
Slide 5: MOA - Phexxi Is a pH Modulator
MOA - PHEXXI IS A pH MODULATOR Optimal vaginal pH levels can range from 3.5 ~ 4.5 Allows sperm to be mobile and swim up the reproductive canal This is lower than published rates of hormonal methods, which range from 9.6% to 20.1% discontinuation due to adverse reactions
Slide 6: Every 1% Market Share of the 43.3M Women in Our Addressable Market
EVERY 1% MARKET SHARE OF THE 43.3M WOMEN IN OUR ADDRESSABLE MARKET REPRESENTS SIGNIFICANT NET PRODUCT SALES Paid by the plan, not the woman GROSS WAC $348,241 5 Under Federal law, most payers must cover FDA-approved ta Ee contraceptives, including Phemi, at no cost to women Gross-to-Net Adjustments
Slide 7: Net Product Sales Growth Since Launch
NET PRODUCT SALES GROWTH SINCE LAUNCH e fexr! Three consecutive years of revenue growth “ $18.2 $16.8 - $8.2 soa J FY 2020 FY 2021 FY 2022 FY 2023 In tions
Slide 8: Net Product Sales Now Exceed Sales & Marketing Cost
NET PRODUCT SALES NOW EXCEED SALES & MARKETING COST Quarterly selling and marketing expense as a percent of net product sales $127 ™@ Product sales, net san ann = Selling and Marketing 6 $70 2 $6.4 Eo a ssa C ssa a so a $3.9 330 25 4) 26 os | | | aaron ca202 3202 as202 curs aaron 3203 as208 299% 204
Slide 9: Activating Select Patient Types to Use Phexxi
ACTIVATING SELECT PATIENT TYPES TO USE PHEXXI w aligned with the current Phexxi LIVING ae ] DEPRESSION AND ANKIETY + cepltaizingon where Phevdis already performing, STRUGGLES WITH HER WEIGHT ‘CONTRACEPTION + The majority of Phexxi patients are within the 25-39 age ame /ANTS NON-HORMONAL Average age
Slide 10: Activating Phexxi Utilization with Select Patient Types
ACTIVATING PHEXXI UTILIZATION WITH SELECT PATIENT TYPES Prior Contraception Among Women Switching to Phexxi? pert fee acid, citric acid, and potassium bitartrate) Vaginal Gel 1.8%, 1%, 0.4%. 80.6% 1.7% x contraception rings and patches 9.9% 7 smiratones — @Y78% contraceptive GET PATIENT TYPES. 1:10
Slide 11: Creating the Vaginal pH Modulator Category
CREATING THE VAGINAL PH MODULATOR CATEGORY Changing the contraceptive counseling conversation to make it personal HORMONE FREE BIRTH CONT! BIRTH CONTROL Is PERSONAL. wich METHOD" MEETS Your NEEDS?
Slide 12: The GLP-1 Opportunity
THE GLP-1 OPPORTUNITY Glucagon-like peptide-1 (GLP-1) agonists include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) 1. Help lower blood sugar levels to treat type 2 diabetes (T2D) - Currently used by around 10-12% of T2D patients in the U.S.2 2. Suppress appetite and reduce cal
Slide 13: Leveraging the GLP-1 Opportunity for Phexxi
LEVERAGING THE GLP-1 OPPORTUNITY FOR PHEXXI * GLP-1 receptor agonists may make oral birth control pills less effective at certain points in dosing schedule Mounjaro and Zepbound (tirzepatide) clearly instruct HCPs to “advise females using oral contraceptives to switch to a non-oral contraceptive met
Slide 14: $224.56 Million Near-Term GLP-1 U.S. Opportunity
$224.56 MILLION NEAR-TERM GLP-1 U.S. OPPORTUNITY 2030 Forecast (U.S.) Sere -1 Users Women of Reproductive Age as % of U.S. Adult Population Female GLP-1 Users of Reproductive Age % of Women of Reproductive Age using Oral Contraceptives (OCs) ,074,708 ett" targets Women on GLP-1s using OCs = $224.56M
Slide 15: Leveraging the OTC Opill Opportunity
LEVERAGING THE OTC OPILL OPPORTUNITY * The progestin-only oral contraceptive Opill became available over-the-counter (OTC) in March 2024 * Opill must must be taken within the same 3-hour window each day * Opill users are instructed to use a barrier method for added protection every time they have se
Slide 16: Phexxi Sales Coverage
PHEXXI SALES COVERAGE L_] Field Coverage (n=16) Virtual Coverage @ | strategic initiatives Student Health & Residency Programs
Slide 17: Increasing Phexxi Access
INCREASING PHEXX! ACCESS More than 82% of Phexxi claims are now being approved? YTD 2023 Evofem has gained Phexxi coverage for more than 21.3M new lives? We have 73% coverage within our Commercial and Medicaid books of business* + 19.2M lives covered at no out-of-pocket cost? Co-pay card utilization
Slide 18: Intellectual Property Protects Phexxi into at Least 2033
INTELLECTUAL PROPERTY PROTECTS PHEXXI INTO AT LEAST 2033 Four Orange Book listed patents on using the L-Lactic nulation Method of use patent cove ‘Acid Phexxi formulation 1g contraception using the L-Lactic Expected to provide protection into at least March 2033 11,439,610 Composition of matter pate
Slide 19: Why Evofem? Why Now?
WHY EVOFEM? WHY NOW? Shattering The Hormone Glass Ceiling With First-in-class Product Attractive Target Market Hormone-ree Fi A small percentage of market share tive that i Yields large revenue Ex US license opportunities Intellectual Property protection into at least 2033, st birth control industry
Slide 20: Thank You
E¥OFEM BIOSCIENCES THANK YOU
Evofem Biosciences — Investor Presentation (March 2024) on 6ix